Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases

Neuroscientist

Volumn 14, Issue 3, 2008, Pages 240-250

  Gardiner, John ^a   Barton, Deborah ^a   May Vanslambrouck, Jessica ^a   Braet, Filip ^a   Hall, David ^b   Marc, Jan ^a   Overall, Robyn ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Neutral Bay Australia   (Australia)

Author keywords

Familial dysautonomia; Fungiform papillae; Neurological disease; Neurotrophic support; Taste

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTIDEPRESSANT AGENT; EBSELEN; EPIGALLOCATECHIN GALLATE; FLUOXETINE; IKAP PROTEIN; KERATIN; NEUROTROPHIN; NORPHENAZONE; PAROXETINE; PROTEIN DERIVATIVE; RANIRESTAT;

ALZHEIMER DISEASE; AUTONOMIC NEUROPATHY; BECKWITH WIEDEMANN SYNDROME; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CYTOSKELETON; DIABETES MELLITUS; DYSAUTONOMIA; DYSTONIA; HELA CELL; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MACHADO JOSEPH DISEASE; NEUROPATHY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SENSORY SYSTEM; TASTE; TASTE BUD; TASTE DISORDER; TONGUE DISEASE;

ANIMALS; CARRIER PROTEINS; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; KERATINS; NERVE GROWTH FACTORS; NERVOUS SYSTEM DISEASES; TASTE BUDS; TASTE DISORDERS; TONGUE;

EID: 43049112072     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858407312382     Document Type: Review

References (122)

1. Alpagut U., Ugurlucan M., Dayioglu E. 2007. Major arterial involvement and review of Behçet's disease. Ann Vasc Surg 21: 232-9.
2. Anderson SL, Qiu J., Rubin BY 2003. EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 310: 627-33.
3. Baker SA, Stanford LE, Brown RE, Hagg T. 2005. Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice. Brain Res 1039: 177-88.
4. Bhattacharyya A., Watson FL, Pomaeroy SL, Zhang YZ, Stiles CD, Segal RA 2002. High-resolution imaging demonstrates dyneinbased vesicular transport of activated Trk receptors. J Neurobiol 51: 302-12.
5. Bril V., Buchanan RA 2006. Long-term effects of Ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29: 68-72.
6. Burnett B., Li F., Pittman RN 2003. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitinylated proteins and has ubiquitin protease activity. Hum Mol Genet 12: 3195-205.
7. Cacquevel M., Lebeurrier N., Cheenne S., Vivien D. 2004. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 5: 529-34.
8. Cafferty WBJ, Gardiner NJ, Das P., Qiu J., McMahon SB, Thompson SWN. 2004. Conditioning injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. J Neurosci 24: 4432-43.
9. Calcutt NA, Freshwater JD, Mizisin AP 2004. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47: 718-24.
10. Carroll P., Lewin GR, Koltzenburg M., Toyka KV, Thoenen H. 1998. A role for BDNF in mechanosensation. Nat Neurosci 1: 42-6.
11. Cha GH, Kim S., Park J., Lee E., Kim M., Lee SB, and others. 2005. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci 102: 10345-50.
12. Chai Y., Shao J., Miller VM, Williams A., Paulson HL 2002. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci 99: 9310-5.
13. Chen ZY, Patel PD, Sant G., Meng CX, Teng KK, Hempsted BL, and others. 2004. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24: 4401-11.
14. Chen Z., Simmons MS, Perry RT, Wiener HW, Harrell LE, Go RC 2007. Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (in press).
15. Close P., Hawkes N., Comez I., Creppe C., Lambert CA, Rogister B., and others. 2006. Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell 22: 521-31.
16. Dagoneau N., Scheffer D., Huber C., Al-Gazali LI, Di Rocco M., Godard A., and others. 2004. Null leukaemia inhibitory factor receptor (LIFR) mutations in Stüve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet 74: 298-305.
17. Davis E., Melzer E. 1969. A new sign in Behçet's syndrome: scanty fungiform papillae in tongue. Arch Int Med 124: 720-1.
18. DeChiara TM, Vejsada R., Poueymirou WT, Acheson A., Suri C., Conover JC, and others. 1995. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell 83: 313-22.
19. De Grandis D. 2007. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 21 Suppl 1: 39-43.
20. Deogracias R., Espliguero G., Iglesias T., Rodríguez-Peña A. 2004. Expression of the neurotrophin receptor trkB is regulated by the cAMP/CREB pathway in neurons. Mol Cell Neurosci 26: 470-80.
21. De Repentigny Y., Deschenes-Furry J., Jasmin BJ, Kothary R. 2003. Impaired fast axonal transport in neurons of the sciatic nerves from dystonia musculorum mice. J Neurochem 86: 564-71.
22. Dick FD, Seaton A., Haites N., Semple SE, Dick S., Prescott GJ, and others. 2007. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med (in press).
23. Di Rocco M., Stella G., Bruno C., Doria Lamba L., Bado M., Superti-Furga A. 2003. Long-term survival in Stüve-Wiedemann syndrome: a neuro-myo-skeletal disorder with manifestations of dysautonomia. Am J Med Genet A 118: 362-8.
24. Doty RL, Bagla R., Morgenson M., Mirza N. 2001. NaCl thresholds: relationship to anterior tongue locus, area of stimulation, and number of fungiform papillae. Physiol Behav 72: 373-8.
25. Duan W., Guo Z., Jiang H., Ladenheim B., Xu X., Cadet JL, and others. 2004. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55: 590-4.
26. Ehrnhoefer DE, Duennwald M., Markovic P., Wackeri JL, Engemann S., Roark M., and others. 2006. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 15: 2743-51.
27. Emerich DF, Winn SR, Hantraye PM, Peschanski M., Chen EY, Chu Y., and others. 1997. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386: 395-9.
28. Emtage L., Gu G., Hartwieg E., Chalfie M. 2004. Extracellular proteins organize the mechanosensory channel complex in C. elegans touch receptor neurons. Neuron 44: 795-807.
29. Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L., de Vos RA, Brunt ER, and others. 2003. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 62: 1006-18.
30. Evert BO, Vogt IR, Kindermann C., Ozimek L., de Vos RAI, Brunt ERP, and others. 2001. Inflammatory genes are upregulated in expanded ataxin-3-expression cell lines and spinocerebellar ataxia type 3 brains. J Neurosci 21: 5389-96.
31. Finkbeiner S., Tavazoie SF, Maloratsky A., Jacobs KM, Harris KM, Greenberg ME 1997. CREB: a major mediator of neuronal neurotrophin responses. Neuron 19: 1031-47.
32. Fukutake T., Kita K., Sakakibara R., Takagi K., Tokumaru Y., Kojima S., and others. 1996. Late-onset hereditary ataxia with global thermoanalgesia and absence of fungiform papillae on the tongue in a Japanese family. Brain 119: 1011-21.
33. Gardiner JC, Barton D., Marc J., Overall R. 2007. Potential role of tubulin acetylation and microtubule-based protein trafficking in familial dysautonomia. Traffic 8: 1145-9.
34. Garzon DJ, Fahnestock M. 2007. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27: 2628-35.
35. Gauthier LR, Charrin BC, Borrell-Pagés M., Dompierre JP, Rangone H., Cordeliéres FP, and others. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-38.
36. Graziadei PP 1969. The ultrastructure of mammalian taste receptors. Ann Intern Med 71: 807-14.
37. Grote HE, Bull ND, Howard ML, van Dellen A., Blakemore C., Bartlett PF, and others. 2005. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 22: 2081-8.
38. Hagel C., Stavrou D. 2007. Neuronal markers in non-neuronal tissues. Prog Exp Tumor Res 39: 64-77.
39. Hashimoto M., Hsu LJ, Rockenstein E., Takenouchi T., Mallory M., Masliah E. 2002. α-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 277: 11465-72.
40. Hibbert AP, Kramer BM, Miller FD, Kaplan DR 2006. The localization, trafficking and retrograde transport of BDNF bound to p75NTR in sympathetic neurons. Mol Cell Neurosci 32: 387-402.
41. Holmberg C., Katz S., Lerdrup M., Herdegen T., Jäätelä M., Aronheim A., and others. 2002. A novel specific role of IκB kinase complex-associated protein in cytosolic stress signaling. J Biol Chem 277: 31918-28.
42. Hopkinson SB, Jones JC 2000. The N terminus of transmembrane protein BP180 interacts with the N-terminal domain of BP230, thereby mediating keratin cytoskeleton anchorage to the cell surface at the site of the hemidesmosome. Mol Biol Cell 11: 277-86.
43. Howells DW, Porritt MJ, Wong JYF, Batchelor PE, Kalnins R., Hughes AJ, and others. 2000. Reduced BDNF mRNA expression in Parkinson's disease substantia nigra. Exp Neurol 166: 127-35.
44. Huntington's Disease Association. 2007. Huntington's Disease Association Fact Sheet 7. http://huntingtondisease.tripod.com/swallowing/id43.html
45. Ichikawa H., Terayama R., Yamaai T., De Repentigny Y., Kothary R., Sugimoto T. 2007. Dystonin deficiency reduces taste buds and fungiform papillae in the anterior part of the tongue. Brain Res 1129: 142-6.
46. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S., Kakizuka A. 1996. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 13: 196-202.
47. Indo Y., Tsuruta M., Hayashida Y., Karim MA, Ohta K., Kawano T., and others. 1996. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 13: 485-8.
48. Ingber DE 1997. Integrins, tensegrity, and mechanotransduction. Gravit Space Biol Bull 10: 49-55.
49. Ip NY, Nye SH, Boulton TG, Davis S., Taga T., Li Y., and others. 1992. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 69: 1121-32.
50. Kalayciyan A., Zouboulis CC 2007. An update on Behçet's disease. J Eur Acad Dermatol Venereol 21: 1-10.
51. Karamohamed S., Latourelle JC, Racette A., Perlmutter JS, Wooten GF, Lew M., and others. 2005. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD study. Neurology 65: 1823-5.
52. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., and others. 1994. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 Nat Genet 8: 221-8.
53. Kim SG, Lee CH, Park JW 2004. Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation. J Toxicol Environ Health A 67: 2013-24.
54. Kim S-J., Jeong H-J., Lee K-M., Myung N-Y., An N-H., Yang WM, and others. 2007. Epigallocatechin-3-gallate suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18: 587-96.
55. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher MG, Lang AE 2007. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6: 652-62.
56. Kuruvilla R., Zweifel LS, Glebova NO, Lonze BE, Valdez G., Ye H., and others. 2004. A neurotrophin signaling cascade coordinates sympathetic neuron development through differential control of TrkA trafficking and retrograde signalling. Cell 118: 243-55.
57. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, and others. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370: 223-6.
58. Lasek K., Klein C., Gaser C., Hilker R., Hagenah J., van Eimeren T., and others. 2007. Increased gray matter volume of the basal ganglia-a morphometric fingerprint of presymptomatic compensation in genetically determined parkinsonism. Clin Neurophysiol 118: e67-8.
59. Lee W-C M., Yoshihara M., Littleton JT 2004. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci 101: 3224-9.
60. Le Floch JP, Le Lievre G., Sadoun J., Perlmuter L., Peynegre R., Hazard J. 1989. Taste impairment and related factors in type I diabetes mellitus. Diabetes Care 12: 173-8.
61. Leiba M., Ehrenfeld M. 2005. Behçet's disease: current therapeutic perspectives. Curr Treat Options Cardiovasc Med 7: 139-48.
62. Liebl DJ, Mbiene JP, Parada LF 1999. NT4/5 mutant mice have deficiency in gustatory papillae and taste bud formation. Dev Biol 213: 378-89.
63. Liu J., Ding J., Kowal A., Nardine T., Allen E., Delcroix J., and others. 2003. BPAG1n4 is essential for retrograde axonal transport in sensory neurons. J Cell Biol 131: 1315-26.
64. Longo F., Mizisin A. 2004. Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF. United States Patent 6696407.
65. Lucas PD, Qirbi A. 1989. Tissue noradrenaline and the polyol pathway in experimentally diabetic rats. Br J Pharmacol 97: 347-52.
66. Ma L., Xu J., Coulombe PA, Wirtz D. 1999. Keratin filament suspensions show unique micromechanical properties. J Biol Chem 274: 19145-51.
67. McCampbell A., Fischbeck KH 2001. Polyglutamine and CBP: fatal attraction ? Nat Med 7: 528-30.
68. Maimone D., Cioni C., Rosa S., Macchia G., Aloisi F., Annunziata P. 1993. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1beta and TNF alpha. J Neuroimmunol 47: 73-81.
69. Manna SK, Mukhopadhyay A., Aggarwal BB 2000. Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB, activator protein-1, c-Jun N-terminal kinase, and apoptosis. J Immunol 165: 5962-9.
70. Martinowich J., Lu B. 2007. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology (in press).
71. Mbiene J. -P, Roberts JD 2003. Distribution of keratin 8-containing cell clusters in mouse embryonic tongue: evidence for a prepattern for taste bud development. J Comp Neurol 457: 111-22.
72. Metzler C., Arlt AC, Gross WL, Brandt J. 2005. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Diseases 64: 1798-1800.
73. Miyata K., Omori N., Uchino H., Yamaguchi T., Isshiki A., Shibasaki F. 2001. Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotective effect of cyclosporine A in forebrain ischemia. Neuroscience 105: 571-8.
74. Mizisin AP, Calcutt NA, DiStefano PS, Acheson A., Longo FM 1997. Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes 46: 647-52.
75. Mizisin AP, Vu Y., Shuff M., Calcutt NA 2004. Ciliary neurotrophic factor improves nerve conduction and ameliorates regeneration deficits in diabetic rats. Diabetes 53: 1807-12.
76. Monte TL, Rieder CRM, Tort AB, Rockenback I., Pereira ML, Silveira I., and others. 2003. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 107: 207-10.
77. Morrison B. 3rd, Meaney DF, Margulies SS, McIntosh TK 2000. Dynamic mechanical stretch of organotypic brain slice cultures induces differential genomic expression: relationship to mechanical parameters. J Biomech Eng 122: 224-30.
78. Nelson RL, Guo Z., Halagappa VM 2007. Prophylactic treatment with paroxetine ameliorates behavioural deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 205: 166-76.
79. Noh JS, Kang HJ, Kim EY, Sohn S., Chung YK, Kim SU, and others. 2000. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH2-terminal protein kinase. J Neurochem 75: 2327-34.
80. Nosrat CA 1998. Neurotrophic factors in the tongue: expression patterns, biological activity, relation to innervation and studies of neurotrophin knockout mice. Ann NY Acad Sci 855: 28-49.
81. Nosrat CA, Blomlöf J., El Shamy WM, Ernfors P., Olson L. 1997. Lingual deficits in BDNF and NT3 mutant mice leading to gustatory and somatosensory disturbances, respectively. Development 124: 1333-42.
82. Oakley B. 1993. The gustatory competence of the lingual epithelium requires neonatal innervation. Brain Res 72: 259-64.
83. Oakley B., Chu JS, Jones LB 1981. Axonal transport maintains taste responses. Brain Res 221: 289-98.
84. Oakley B., Witt, M. 2004. Building sensory receptors on the tongue. J Neurocytol 33: 631-46.
85. Obrosova IG, Van Huysen CV, Fathallah L., Cao X., Greene DA, Stevens MJ 2002. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16: 123-5.
86. Oliva AA Jr, Atkins CM, Copenagle L., Banker GA 2006. Activated c-Jun N-terminal kinase is required for axon formation. J Neurosci 26: 9462-70.
87. Pai MH, Ko TL, Chou HC 2006. Effects of streptozotocin-induced diabetes on taste buds in rat vallate papillae. Acta Histochem 109: 200-7.
88. Panicker JN, Vinayan KP, Ahsan Moosa NV, Elango EM, Kumar AA 2007. Juvenile Behçet's disease: highlighting neuropsychiatric manifestations and putative genetic mechanisms. Clin Neurol Neurosurg 109: 436-8.
89. Pearson J., Axelrod F., Dancis J. 1974. Trophic functions of the neuron. V. Familial dysautonomis. Current concepts of dysautonomia: neuropathological defects. Ann NY Acad Sci 228: 288-300.
90. Peng J., Mao XO, Stevenson FF, Hsu M., Andersen JK 2004. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 279: 32626-32.
91. Phillips HS, Hains JM, Armanini M., Laramee GR, Johnson SA, Winslow JW 1991. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702.
92. Pool M., Rippstein P., McBride H., Kothary R. 2006. Trafficking of macromolecules and organelles in cultured Dystonia musculorum sensory neurons is normal. J Comp Neurol 494: 549-58.
93. Quaranta V., Jones JC 1991. The internal affairs of an integrin. Trends Cell Biol 1: 2-4.
94. Reutter K., Witt M. 1993. Morphology of vertebrate taste organs and their nerve supply. In: SA Simon and SD Roper, editors. Mechanisms of taste transduction. Boca Raton, FL, Ann Arbor MI, London, and Tokyo: CRC Press. P 29-82.
95. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D. 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25: 8807-14.
96. Roberts DS, Hu Y., Lund IV, Brooks-Kayal AR, Russek SJ 2006. Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J Biol Chem 281: 29431-5.
97. Saudou F., Finkbeiner S., Devys D., Greenberg ME 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranculear inclusions. Cell 95: 55-66.
98. Sawamura D., Li K., Chu ML, Uitto J. 1991. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 266: 17784-90.
99. Scheel H., Tomiuk S., Hofmann K. 2003. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet 12: 2845-52.
100. Schulte-Herbrüggen O., Nassenstein C., Lommatzsch M., Quarcoo D., Renz H., Braun A. 2005. Tumor necrosis factor-α and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 160: 204-9.
101. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., and others. 2004. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53: 2412-9.
102. Shaftel SS, Kyrkanides S., Olschowka JA, Miller JN, Johnson RE, O'Banion MK 2007. Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595-1604.
103. Shuto T., Horie H., Hikawa N., Sango K., Tokashiki A., Murata H., and others. 2001. IL-6 up-regulates CNTF mRNA expression and enhances neurite regeneration. NeuroReport 12: 1081-5.
104. Sienkiewicz-Jarosz H., Scinska A., Kuran W., Ryglewicz D., Rogowski A., Wrobel E., and others. 2005. Taste responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 76: 40-6.
105. Silverberg NB, Singh A., Echt AF, Laude TA 1996. Lingual fungiform papillae hypertrophy with cyclosporin A. Lancet 348: 967.
106. Sima AA 2007. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 21 Suppl 1: 13-23.
107. Smith AA, Dancis J. 1964. Exaggerated response to infused norepinephrine in familial dysautonomia. N Engl J Med 270: 704-7.
108. Stüve A., Wiedemann H-R. 1971. Congenital bowing of the long bones in two sisters. Lancet 2 (7722). 495.
109. Tao X., Finkbeiner S., Arnold DB, Shaywitz AJ, Greenberg ME 1998. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20: 709-26.
110. Uchiyama T., Fukutake T., Arai K., Nakagawa K., Hattori T. 2001. Machado-Joseph disease associated with an absence of fungiform papillae on the tongue. Neurology 56: 558-60.
111. Wang N., Butler JP, Ingber DE 1993. Mechanotransduction across the cell surface and through the cytoskeleton. Science 260: 1124-7.
112. Wen J., Watanabe K., Ma M., Yamaguchi K., Tachikawa H., Kodama M., and others. 2006. Edaravone inhibits JNK-c-Jun pathway and restores anti-oxidative defense after ischemica-reperfusion in aged rats. Biol Pharm Bull 29: 713-8.
113. Wolfe SM, Henkin RI 1970. Absence of taste in type II familial dysautonomia: unresponsiveness to methacholine despite the presence of taste bud. J Pediatr 77: 103-8.
114. Wrathall JR 1986. Reduced neuronotrophic activity of fibroblasts from individuals with dysautonomia in cultures of newborn mouse sensory ganglion cells. Brain Res 364: 23-9.
115. Yamagishi M., Takami S., Getchell TV 1995. Innervation in human taste buds and its decrease in Alzheimer's disease patients. Acta Otolaryngol 115: 678-84.
116. Yazici H., Fresko I., Yurdakul S. 2007. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3: 148-55.
117. Yee C., Bartel DL, Finger TE 2005. Effects of glossopharyngeal nerve section on the expression of neurotrophins and their receptors in lingual taste buds of adult mice. J Comp Neurol 490: 371-90.
118. Yoshizumi M., Kogame T., Suzuki Y., Fujita Y., Kyaw M., Kirima K., and others. 2002. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br J Pharmacol 136: 1023-32.
119. Young KG, Kothary R. 2007. Dystonin/Bpag1- a link to what? Cell Motil Cytoskeleton (in press).
120. Zeng Q., Lawton A., Oakley B. 1995. Glycoconjugates and keratin 18 define subsets of differentiated taste cells of the rat. Differentiation 58: 341-9.
121. Zhang C., Brandemifl, Lau D., Lawton A., Oakley B. 1997. BDNF is required for the normal development of taste neuron in vivo. Neuroreport 8: 1013-7.
122. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., and others. 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled genes. Nat Genet 35: 76-83.